Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» MorphoSys
MorphoSys
Novartis in the lead to acquire cancer drug developer MorphoSys-sources
NASDAQ.com/Reuters
Mon, 02/5/24 - 11:28 am
Novartis
M&A
MorphoSys
cancer
MorphoSys’ pelabresib meets endpoints in Phase III myelofibrosis trial
Clinical Trials Arena
Tue, 11/21/23 - 11:55 am
MorphoSys
clinical trials
pelabresib
myelofibrosis
MorphoSys Cuts Pre-Clinical Programs, 17% of Staff
BioSpace
Thu, 03/2/23 - 10:46 pm
MorphoSys
layoffs
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
MedCity News
Tue, 11/1/22 - 10:55 am
Human Immunology Bioscience
autoimmune disease
R&D
MorphoSys
kidney disease
MorphoSys Adds HIBio to Busy Collaboration Week
BioSpace
Wed, 06/15/22 - 11:03 am
MorphoSys
HIBio
Pfizer
Incyte
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
MorphoSys cuts R&D from Constellation deal to focus on clinical-stage cancer drugs
MedCity News
Fri, 03/11/22 - 10:42 am
MorphoSys
drug discovery
R&D
Constellation Pharmaceuticals
M&A
In a quiet year for takeouts, who was buying?
EP Vantage
Fri, 01/28/22 - 09:54 am
M&A
Jazz Pharmaceuticals
Horizon Pharma
MorphoSys
BioMarin stands tall with first approved drug for rare disease that causes dwarfism
MedCity News
Sat, 08/28/21 - 08:57 pm
Biomarin
Europe
achondroplasia
dwarfism
Incyte
MorphoSys
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
BioPharma Dive
Tue, 08/10/21 - 11:12 pm
M&A
Bayer
Sanofi
Amgen
uniQure
MorphoSys
Xeris Pharmaceuticals
Relay Therapeutics
Merck
Beam Therapeutics
Jazz Pharmaceuticals
Biopharma takeovers dry up
EP Vantage
Mon, 07/5/21 - 09:50 pm
M&A
MorphoSys
Constellation Pharmaceuticals
Sanofi
Tidal Therapeutics
uniQure
Corlieve Therapeutics
Strongbridge Biopharma
Xerix Pharmaceuticals
Novellus Therapeutics
Brooklyn Immunotherapeutics
Morphosys to buy Constellation in $1.7B deal, aided by unusual funding
BioPharma Dive
Wed, 06/2/21 - 12:10 pm
MorphoSys
M&A
Constellation Pharmaceuticals
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
Tue, 09/22/20 - 10:15 pm
FDA
Kite Pharma
Tecartus
Novartis
Kesimpta
MorphoSys
Monjuvi
OptumRx
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
Mon, 08/3/20 - 10:14 am
FDA
Monjuvi
CAR-T
MorphoSys
Incyte
diffuse large B-cell lymphoma
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
Mon, 03/2/20 - 09:37 am
MorphoSys
Gilead Sciences
Novartis
CAR-T
tafasitamab
DLBCL
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Mon, 01/13/20 - 11:51 pm
Incyte
MorphoSys
lymphoma
tafasitamab
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Fierce Biotech
Tue, 10/29/19 - 09:57 am
MorphoSys
Galapagos
Novartis
MOR106
atopic dermatitis
Dupixent
Sanofi
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 06/16/19 - 05:41 pm
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Morphosys to take on CAR-Ts in NHL with promising antibody
Pharmaforum
Mon, 05/20/19 - 11:02 pm
MorphoSys
Celgene
Revlimid
non-Hodgkin lymphoma
clinical trials
tafasitamab
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Endpoints
Fri, 05/17/19 - 01:03 pm
CAR-T
MorphoSys
Novartis
Gilead Sciences
tafasitamab
DLBCL
Pages
1
2
3
next ›
last »